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Objective: We evaluated the influence of placement of the bifurcated Powerlink endograft (Endologix Inc, Irvine, Calif)
on the aortic bifurcation, with the addition of a proximal extension, in the endovascular treatment (EVAR) of selected
patients with atherosclerotic abdominal aortic aneurysms (AAAs).
Methods: From September 1999 to June 2007, 205 patients were treated with the bifurcated Powerlink endograft for
atherosclerotic AAA at two Italian centers with shared protocols. Patients were retrospectively divided in two groups
according to treatment with the bifurcated graft only (n  126), or its placement on the bifurcation with the addition of
a proximal extension (n  79) at the initial procedure. Study end points included postoperative complications, secondary
procedures, immediate and late conversion, migration, endoleak, death, and aneurysmal sac behavior.
Results: Overall technical success was 98.5%. Additional procedures were performed in 18%, and postoperative compli-
cations occurred in 11.2% (systemic, 8.3%; local, 2.9%). Median follow-up was 42.4 months (range, 6-94 months).
Secondary procedures were recorded in 11.2%, migration in 3.9%, type I proximal endoleak in 7.8%, and late conversions
in 2.4%. Placement on the bifurcation and the addition of an extension were associated with a higher incidence of
postoperative complications (7.1% vs 17.7%, P  .020). A reduced incidence of endoleak (19% vs 8.9%, P  .048),
secondary procedures (14.3% vs 6.3%, P  .04), and migration (6.3% vs 0%, P  .024) were observed in the group with
a proximal extension. Analysis of single variables reveals that migration was significantly influenced by placement of the
graft on the bifurcation (47% vs 0%, P < .001). Both placement on the bifurcation and the addition of an extension
positively influenced the type I proximal endoleak rate (3.8% vs 35.3% P < .001) and the need for a secondary intervention
(6.3% vs 35.3% P < .001) Two aneurysm ruptures and five cases of late conversion occurred in the group treated with a
bifurcated graft only (4%, P  .52, P  .159). Analysis of aneurysm sac behavior was not statistically significant:
enlargement, 4.1% vs 1.3% (P  .158); reduction, 34.1% vs 40.5% (P  .542).
Conclusion: The placement of the bifurcated Powerlink endograft on the aortic bifurcation with a proximal extension for
complete sealing seems to improve late outcomes, particularly secondary procedures, migration, and endoleak develop-
ment. Larger prospective studies with longer follow-up are necessary to confirm these promising results. ( J Vasc Surg
2008;48:795-801.)Immediate results associated with endovascular treat-
ment (EVAR) for abdominal aortic aneurysms (AAAs)
during the 1990s were encouraging,1-3 but mid-term re-
sults of the first- and second-generation endoprosthesis4-9
called into question the longer-term suitability of the treat-
ment. Hence, commercial manufacturers promptly en-
hanced the endoprostheses to improve common failures
and enhance their efficacy into the mid- to long-term.
Recently, EVAR 110 and EVAR 2,11 multicenter
randomized controlled trials comparing open treatment
and EVAR for AAA, reported significantly lower rates
associated with EVAR for postoperative complications
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doi:10.1016/j.jvs.2008.05.011and aneurysm-related postoperative death. Several de-
vices have been evaluated in clinical trials10-19 and are
currently available on the market.
The Powerlink device (Endologix Inc, Irvine, Calif) is a
unique, unibody bifurcated endograft that has been com-
mercially available in Europe since 1999. Prospective mul-
ticenter18,19 and single-center trials20 have studied the
safety and efficacy of the device for immediate and mid-
term follow-up in selected patients.
We present our study as an analysis of the best deploy-
ment technique for the unibody bifurcated Powerlink en-
dograft at primary, elective EVAR in selected low- and
high-risk patients with atherosclerotic AAA. The analysis
includes the influence on immediate and late outcomes of
the addition of a proximal extension and the placement of
the main body of the graft at the aortic bifurcation.
METHODS
From September 1999 to June 2007, 283 patients were
treated with EVAR using the Powerlink endograft in two
Italian centers. Of these, 205 were treated for atheroscle-
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the subject of this study. The remaining 79 patients were
treated with a straight tube (n  25), an aortomonoiliac
graft (n  4), and for other abdominal aortic diagnoses
(n  49), such as inflammatory AAA, symptomatic or
ruptured AAA, pseudoaneurysms, and dissections.
Anatomic inclusion and exclusion criteria have previ-
ously been defined by Carpenter and Albertini.18-19,21-22
Our treatment group included patients treated outside of
these criteria: 4.4% (9 of 205) with abdominal aortic necks
that were extremely short (range, 10-14 mm), straight
(30°), and without calcification, and 31% of patients with
narrow necks (range, 18-21 mm) or wide necks (range,
27-32 mm). Descriptions of the device and the operative
deployment procedures have already been published.21,23
All of the patients were studied preoperatively with
computed tomography angiography (CTA) (98%) or
magnetic resonance angiography (2%). All procedures
were performed in a dedicated vascular operating room
equipped with mobile C-Arm (OEC 9800, GE Medical
System, Salt Lake City, Utah), IVUS (Volcano s5, Ran-
cho Cordova, Calif), and echo duplex scanner (Esaote
AU 5, Genova. Italy).
The EVAR teams include two vascular surgeons (at least
one endovascular expert), an anesthesiologist, an endovascu-
larly trained operating nurse, and a radiology technician. The
centers have two surgeons who work at both locations.
All patients underwent a postoperative abdominal radi-
ography before hospital discharge. Our follow-up protocol
in both centers includes a physical examination, abdominal
four-view radiography, and CTA at 1, 6, and 12 months,
and then a biannual abdominal radiography and annual
CTA. Throughout the follow-up, the maximum aneurysm
diameter and position of the endograft in relation to the
most distal renal artery were measured and recorded in 154
of the 205 patients. In recent years CTA has been replaced
with an annual echo duplex scan, reserving the CTA for
patients in whom endoleak or anatomic changes are sus-
pected, such as aneurysm diameter enlargement (5 mm),
aortic neck dilation, endograft migration (5 mm) and
kinking, and occlusion of the endograft branch. Aneurysm
sac diameter andmigration were defined as an enlargement,
reduction, or slippage of 5 mm as measured at CT com-
pared with preoperative and intraoperative measurements.
All data were prospectively collected at both centers
and registered in an Excel database (Microsoft Inc, Red-
mond, Wash) managed by the same surgeon.
Patients were retrospectively divided into two groups
according to treatment at the primary EVAR: 126 patients
had placement of a single endograft (on the aortic bifurcation
72.5% and above the aortic bifurcation 13.5%), and 79 had an
endograft procedure with a single unibody bifurcated graft
deployed, on the aortic bifurcation, with proximal sealing
established with a proximal extension.
Study end points include postoperative complications,
mortality at 30 days, secondary procedures, conversion,
migration, endoleak, late mortality, and aneurysmal sac
behavior throughout the follow-up period.Statistical analysis was performedwith SPSS 12.0 software
(SPSS Inc, Chicago, Ill). The Kaplan-Meier analysis was used
for the study of survival. Independent factors affecting out-
come were analyzed with binary regression logistics. Covari-
ates resulting with a univariate analysis of0.10were inserted
into a multivariate model, which were calculated with the
c-statistic and Hosmer-Lemeshow. The Cox univariate re-
gression analysis was used to evaluate endoleak and mortality
when variables ofP .10were found.The level of significance
was considered as P .05.
RESULTS
The bifurcated Powerlink device was used to treat 205
patients with atherosclerotic AAAs. Patient demographics,
comorbidities, and preoperative aneurysm anatomic fea-
tures are reported in Table I.
The main aortic body was placed on the aortic bifurca-
tion in 188 (91.7%). A total of 79 patients (38.5%) were
treated with the addition of a proximal extension; of these,
11 were not preoperatively planned but were added intra-
operatively due to the presence of a type I proximal en-
doleak at the final intraoperative angiography, and three
patients (1.5%) had both a proximal and distal extension.
One patient was also treated with a Palmaz stent (Cordis,
Miami Lakes, Fla) to straighten an angulated proximal
aortic neck due to a persistent type I proximal endoleak at
the postprocedural angiography. Intraoperative events are
Table I. Summary of patient demographics,
comorbidities, and preoperative aneurysm anatomic
features
Variable Value
Patients, No. 205
Age, median years (range) 74 (52-91)
Sex, No.
Male 192
Female 13
ASA class, %
1 0.5
2 41.5
3 49
4 9
Comorbidities, %
Diabetes 14
Smoker 24
Hypertension 66
Hyperlipemia 29
Cardiac disease 53
Carotid disease 10
Renal disease 8
Respiratory disease 20
Previous laparotomy 11
Obesity 15
AAA max diameter, mm (range)a 53.78 (39-93)
Neck diameter, mm (range) 23.87 (18-32)
Neck length, mm (range) 26.51 (10-70)
ASA, American Society of Anesthesiologists; AAA, abdominal aortic aneu-
rysm.
a Including blisters.reported in Table II.
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(98.5%). Immediate conversion was performed in three
patients (1.5%). Two endograft technical failures were ex-
perienced at the beginning of our experience with the first
model device, and the third was due to an unintentional
coverage of the renal arteries (Table III). The postoperative
mortality rate was 0.5% (1 of 205).
Endoleaks were noted in five patients at the 30-day CT
scan (primary endoleak rate of 2.4%) and in 31 patients
(15%) at an average follow-up of 42.42 months, with an
endoleak-free survival of 79% at 8 years. All endoleak data
are reported in Table III. No patients were lost to follow-
up, but the measurements of sac behavior for 23.4% were
insufficient for full analysis owing to check-ups performed
at other centers or with echo duplex scanning.
Secondary procedures were necessary in 23 patients
(11.2%), and 31 interventions were required. Surgical pro-
cedures were performed in 10 of 31 cases (32%: 5 type I
proximal endoleak, 3 type II endoleak, and 2 branch occlu-
sions); and in the remaining 21 cases, late complications
were managed by endovascular approaches (68%: 15 type I
proximal endoleak, 5 type I distal endoleaks, and 1 thoracic
dissection). Five late conversions (2.4%) were performed
for persistent type I proximal endoleaks, including four
open conversions after attempted EVAR correction of type
I proximal endoleak and one EVAR conversion. These five
patients had one or more factors of “hostile neck,” as
defined by Chaikof et al.24
The demographic and morphologic characteristics of
the two groups were relatively homogeneous, with a higher
average age (P  .097) and risk in the group of patients
with the addition of an extension (Table IV).
The two groups had similar results in early outcomes
with respect to intraoperative additional procedures and
immediate conversions, but these results are counterpoised
Table II. Operative details
Variable EVAR
Total patients, No. 205
Anesthesia, No.
General 142
Local 62
Epidural 1
Procedural details (range)
Fluoroscopy, minutes 9.62 (2-80)
Volume contrast agent, mL 157.94 (20-430)
Duration skin to skin, minutes 78 (50-450)
Endograft fixation site, %
Infrarenal 68
Suprarenal 32
Endograft composition, % (No.)
Unibody main body 61.5 (126)
Unibody  proximal extension 37 (79)
Combination (proximal  distal) 1.5 (3)
Intra-op details, % (No.)
Additional procedures 18 (37)
Conversion 1.5 (3)a
aOne patient died during the operation.by a significant difference in overall postoperative compli-cations in the second group. This difference was significant
for local complications (0.8% vs 6.3%) but not for systemic
complications (6.3% vs 11.4%; Table IV).
Endograft placement on the bifurcation and the addi-
Table III. Results of endovascular treatment with the
Powerlink bifurcated endograft
Variable Overall
Total patients, No. 205
Immediate conversion, % (No.) 1.5 (3)
Successful graft deployment, % (No.) 98.5 (202)
30-day mortality, % (No.) 0.5 (1)
Aneurysm rupture, % (No.) 1 (2)a
Late conversion, % (No.) 2.4 (5)b
Intra-op additional procedures, % (No.) 18 (37)
Post-op systemic complications, % (No.) 8.3 (17)
Cardiac, No. 3
Renal, No. 3
Pulmonary, No. 2
Postimplantation syndrome, No. 7
Limb thrombosis, No. 2
Post-op local complications, % (No.) 2.9 (6)
Hematoma, No. 2
Infection, No. 2
Pseudoaneurysm, No. 1
Lymphorrhea, No. 1
Reintervention rate
Overall, % (No.) 12.6 (26)
Post-op 30 days, % (No.) 1.5 (3)
Secondary interventions, % (No.) 11.2 (23)
Patients with endoleak, % (No.)c 15 (31)
Type I 10.2 (21)
Proximala 7.8 (16)
Distal 2.4 (5)
Type II 7.3 (15)
Type III 0
Type IV 0
Migration 3.9 (8)
Aneurysmal sac behavior, % (No.)
Augmentation 2.9 (6)
No change 35.6 (73)
Reduction 36.6 (75)
Inconclusived 23.4 (48)
Immediate conversion, No. 3
Hospital stay, mean days (range) 3.79 (1-28)
Overall mortality, % (No.)e 10.2 (21)
Aneurysm-related mortality, % (No.)f 1 (2)
Major organ failure (post-op), No. 1
Renal insufficiency, No. 1
Non-aneurysm-related mortality, % (No.) 9.2 (19)
Cardiac, No. 6
Cancer/tumor, No. 5
Stroke 4
Respiratory insufficiency 3
Sepsisg 1
Average follow-up, months (range) 42.42 (6-93)
aTwo patients treated for a ruptured aneurysm at 12 and 36 months; no
patients died.
bIncludes 1 endovascular conversion.
c5 patients had more than one type of endoleak.
dData on sac aneurysm size was insufficient.
eFollow-up was 42 months.
f30-day mortality from major organ failure plus aneurysm-related mortality
at a distance (renal insufficiency).
gSepsis 2 years after the initial intervention.tional deployment of a proximal extension significantly
easure
JOURNAL OF VASCULAR SURGERY
October 2008798 Coppi et aldecreased the probability that an endoleak would develop
(19% vs 8.9%, P  .048), requiring a secondary procedure
(14.3% vs 6.3%, P .04), and of endograft migration (6.3%
vs 0%, P  .024) throughout the follow-up period. There
was a trend suggesting a better outcome for late conver-
sions. The two cases (1%) of AAA rupture were recorded in
patients treated with a single unibody endograft at 12 and
36months from the intervention. Both patients had missed
the last advised follow-up examination, and both under-
went successful conversion to open surgery after type I
Table IV. Endograft configuration: one-piece device com
Variables One piec
Patients, No. 126
Mean age, years 72.38
ASA, %
2 47
3 45
4 6
Immediate conversion, No. 2
Mortality at 30 days, No. 0
Aneurysm rupture, No. 2
Late conversion, % (No.) 4 (5/12
Intra-op additional procedures, % (No.) 17.5 (22/1
Post-op complications, % (No.) 7.1 (9/12
Systemic 6.3 (8/12
Local 0.8 (1/12
Secondary procedures, % (No.) 14.3 (18/1
Endoleak, % (No.)c 19.0 (24/1
Type I 13.5 (17/1
Proximal 10.3 (13/1
Distal 3.2 (4/12
Type II 9.5 (12/1
Migration, % (No.) 6.3 (8/12
Aneurysmal sac
Immediate conversion, No. 2
No change, % (No.) 36.5 (46/1
Enlargement, % (No.) 4.1 (5/12
Reduction, % (No.) 34.1 (43/1
Inconclusive, % (No.)d 23.8 (30/1
Mortality, % (No.) 9.5 (12/1
Follow-up, months (range) 45.69 (6-93
ASA, American Society of Anesthesiologists.
aIncludes 3 patients treated with both proximal and distal extensions.
bValues of P  .05 were considered significant.
cFive patients had more than 1 type of endoleak.
dInformation on the aneurysm sac was inconclusive owing to inadequate m
Table V. Significant outcomes analyzed according to plac
the use of an extension
One piece
One p
Variables Above Bif On Bif O
Patients, No. 17 109
Endoleak, type I proximal, % (No.) 35.3 (6) 6.4 (7)
Migration, % (No.) 47 (8) 0
Secondary intervention, % (No.) 35.3 (6) 11 (12)
Bif, Bifurcation.proximal endoleaks were found at emergency CTA.The statistically significant late outcomes were analyzed
in a further division of the groups according to single
variables: a single endograft placed above the aortic bifur-
cation (n  17), a single endograft placed on the aortic
bifurcation (n 109), and a single endograft placed on the
bifurcation with the addition of an extension (n 79). The
analysis reveals that placement of the device on the bifurca-
tion with the addition of the proximal extension positively
influenced all three outcomes (Table V).
Statistical significance was not found between the two
d with the one-piece device plus extension
One piece  proximal extensiona Pb
79
74.94 .097
33 .049
54 .200
13 .120
1 .99
1
0 .524
0 .159
19 (15/79) .782
17.7 (14/79) .02
11.4 (9/79) .208
6.3 (5/79) .033
6.3 (5/79) .039
8.9 (7/79) .048
5 (4/79) .06
3.8 (3/79) .09
1.3 (1/79) .651
3.8 (3/79) .125
0 .024
1 .99
34 (27/79) .679
1.3 (1/79) .158
40.5 (32/79) .542
22.8 (18/79) .856
12.7 (10/79)
36.38 (6-93)
ments.
t of the endograft above or on the aortic bifurcation and
proximal
sion P (significance  .05)
(cuff) Above Bif vs on Bif Above Bif vs cuff On Bif vs cuff
(3) .001 .001 .524
.001 .001 .99
(5) .008 .001 .269pare
e
4)
26)
6)
6)
6)
26)
26)
26)
26)
6)
26)
6)
26)
6)
26)
26)
26)
)emen
iece 
exten
n Bif
79
3.8
0
6.3groups with regards to aneurysmal sac behavior throughout
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in the group with an extension experienced sac shrinkage
(34.1% vs 40.5%, P  .542) and a lower percentage of sac
augmentation (4.1% vs 1.3%, P  .158; Table IV). Five of
the six cases of graft augmentation were due to type I
proximal endoleak and the other to endotension.
Data regarding proximal aortic neck dilation revealed
an increase in mean neck dilation throughout the follow-up
of 0.4 mm (23.87 mm vs 24.27 mm). A comparatively
better result of 0.26 mm was noted in the group with an
extension (24.72 vs 24.98mm) compared with 0.41mm in
the group with a single endograft (23.36 vs 23.77 mm).
The all-cause mortality was similar in the two groups;
both groups had two aneurysm-related deaths (Table IV).
DISCUSSION
Authors of published studies7,18-21,25,26 dedicated to
endograft safety and efficacy in the immediate- and mid-
term suggest that the unique structural design of the Pow-
erlink device offers advantages in terms of resistance to
material fatigue and improved protection from AAA rup-
ture, with lower incidences of endoleak and secondary
procedures in selected patients compared with other com-
mercially available endografts. The results of our 8-year
experience confirm the feasibility, safety, and relatively pos-
itive late outcomes of this device.
The high percentage of technical success and the posi-
tive early and late results at follow-up are most likely not
only linked to many factors, including patient selection
based on anatomic measurements, and skill of the surgical
team, but also the structural configuration of the Powerlink
endograft system. The uniqueness of the long body design
makes it possible for different AAA exclusion techniques:
the delivery of a single bifurcated graft close to the most
proximal renal artery, independent of the aortic bifurcation,
or the main aortic body placed on the bifurcation with
proximal sealing with the addition of an extension.
Others authors18,20 have previously reported their
preference of the delivery of the Powerlink endograft
placed on the aortic bifurcation, the “anatomic fixation,”
accompanied with the successive positioning of extensions
for adequate proximal sealing to avoid body displacement.
These studies, however, focused on an analysis of migration
only. Qu et al20 reported a statistically significant difference
in distal migration between patients treated with the Pow-
erlink endograft placed on and placed above the anatomic
bifurcation (P  .001). The French Trial19 and the Amer-
ican Endologix Investigators21 both reported three cases
each of stent graft migration (4.7% and 2.2%, respectively)
in which the endograft was placed above the bifurcation.
Our study confirms results supporting the positioning of
the endograft on the bifurcation: Migration occurred in
eight patients (4%), and all were treated with a single
endograft placed above the bifurcation.
In addition, the unique implantation method of the
Powerlink endograft often leaves a segment of the diseased
aorta uncovered and so explains the relatively high use of
proximal extensions in our study of 38.5%, which is in linewith other authors who report a range of 36.6% to
56.2%.19-20,23,26 Regardless of the high percentage of
proximal cuffs used, no incidence of migration was re-
ported in this group.
With experience, we developed a preference for the
addition of a proximal cuff after placement of the graft on
the bifurcation, which we call a “two-step deployment
procedure,” for various reasons. The data from literature
combined with our personal experience proposed the pos-
sibility of distal migration of the main body not placed on
the bifurcation.18,20-21 In our study, 11 cases of inadequate
proximal sealing were detected after the deployment of the
bifurcated graft, and the addition of an extension was
therefore necessary. When deployment of the endograft is
required close to the most distal renal artery, the use of the
proximal extension is more precise.
The retrospective analysis of our experience showed
that patients treated with the main aortic body placed on
the bifurcation with the addition of a proximal extension
showed significantly improved outcomes throughout the
follow-up in terms of lower endoleak detection (P .048),
a reduced need for secondary procedures (P  .04), and a
lower migration rate (P  .024). These results were
achieved despite a lower incidence of immediate conversion
or additional intraoperative procedures.
A higher percentage of overall postoperative complica-
tions was found in the group with a proximal extension
(P  .02), but this was only significant for local complica-
tions (P  .033) and not for the systemic complications.
The introduction of more than one device in difficult
arterial accesses and the higher exposure time of the femo-
ral artery during a longer procedure could be a possible
hypothesis for this unexpected higher incidence of local
complications. The group with a proximal extension in-
cludes patients with an increased median age and percent-
age of high-risk patients (American Society of Anesthesiol-
ogists category 3 and 4), which could partly explain the
different results regarding systemic complications.
Late conversions were all recorded in the group with a
single endograft, which may be related to the group’s
higher detection of endoleak, migration, and secondary
procedures. The aneurysmal sac behavior of the group with
a proximal extension showed a positive trend towards
greater sac shrinkage and reduced sac enlargement. The
lower incidence in this group of endoleak and graft migra-
tion, which are the most significant events influencing sac
behavior, have surely contributed to these results.
An analysis of the influence of the placement of the
endograft on the bifurcation or above it and the addition of
a proximal extension on late outcomes found that 47% of
the endografts placed above the bifurcation migrate. Place-
ment on the aortic bifurcation influences all three statisti-
cally significant late outcomes, with no incidence of distal
migration (0%), a lower endoleak rate (6.4%), and the need
for a secondary procedure (11%). Therefore, the placement
of the graft bifurcation on the natural anatomic bifurcation
offers improved stability to the device. Further, the addi-
tion of the proximal extension seems to again improve the
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(6.3%). Although the population sizes are small, the data
tend to suggest that even if adequate aortic neck coverage is
obtained with a single endograft placed on the bifurcation,
still greater stability is achieved with the addition of a
proximal cuff.
Studies dedicated to the outcome based on the adjoin-
ing of endovascular extensions are limited and mostly con-
cern those deployed during a secondary procedure.7,27-29
Biebl et al30 evaluated the effects of the adjunctive use of
proximal aortic cuffs for EVAR during primary deploy-
ment. Their use was not found to affect postoperative
survival, type I endoleak rate, or the need for secondary
procedures, but was associated with a higher rate of late
endograft migration. Hobo et al26 analyzed data from the
European Collaborators on Stent-Graft Techniques for
AAA and Thoracic Aortic Aneurysm and Dissection Repair
(EUROSTAR) Registry to study the influence of both
proximal cuffs and iliac limb extensions at primary EVAR.
Data were collected for all types of commercially available
endografts, including 123 Powerlink endografts. The cu-
mulative all-graft analysis (mean follow-up, 21.3 months)
concluded that the use of proximal aortic cuffs did not
influence outcomes. Data collected at our center focuses on
a single endograft with specific characteristics collected
during a longer (mean, 42.42 months), more accurate
follow-up period.
The reasons for different outcomes in the two Power-
link groups are not clear and could be found in the unique
structural device conformation. The association of a long
aortic body and the placement of the graft bifurcation on
the natural anatomic bifurcation seems to offer greater
stability to the device. Although the population sizes are
small, the data tend to suggest that even if adequate aortic
neck coverage is obtained with a single endograft placed on
the bifurcation, greater stability is achieved with the addi-
tion of a proximal cuff.
The placement of the endograft on the bifurcation and
the long aortic body could act against the downward force
of pulsatile blood flow, limiting the effect of distal migra-
tion, which is one of the major causes of endoleak. The
overall 10.2% incidence of type I endoleak in this study is in
line with the average 10.5% rate in literature.31 Thereafter,
maintenance of the natural anatomic shape of a long aortic
body (with long endograft coverage of the aorta and aortic
neck) and the natural bifurcation could preserve natural
aortic laminar blood flow.32 This preservation could reduce
the parietal pressure on both the endograft and the aortic
wall and, therefore, could positively influence the evolution
of the neck and sac behavior over time,23,33 as supported by
data from our study.
Another possible explanation for improved results as-
sociated with the deployment of the proximal extension is
that the “two-step procedure” permits a more accurate and
precise proximal fixation. The deployment systems are dif-
ferent: The main body is deployed from the distal tip to the
proximal one, and the extension is deployed conversely,
that is, from its proximal tip to the distal one; hence, theproximal extension is considered easier and more accurate
to deploy.23
A further consideration is that the Powerlink device
achieves a modular configuration when a proximal cuff is
placed. A long overlap of the segments is mandatory and is
favored by the length of Powerlink proximal cuff (5.5, 7.5,
and 9.5 mm), minimizing the risk of component separa-
tion. With a minimum overlap of 3 cm at our center, no
component separation or disconnection was experienced.
Finally, when compared with other modular devices,
this kind of “anatomic two-step” deployment, together
with the limited diameters and lengths of the main body
and cuffs, makes the Powerlink device easier to size and
implant.20 During the implantation process, attention
should be mainly focused on the aortic body length; prox-
imal cuffs should be delivered just below the most distal
renal artery, resulting in both reduced operative time and
volume of contrast medium.18,19,34
CONCLUSION
The data from this study suggest that the best deploy-
ment method for the Powerlink endograft includes placing
of the device on the natural aortic bifurcation, thereby
avoiding distal migration and reducing the incidence of
proximal endoleak and the need for secondary procedures,
with the addition of the proximal extension further improv-
ing these late outcomes. Prospective studies with longer
follow-up are necessary to confirm these results. The signif-
icant difference in late outcomes encourages the selection
of the “two-step anatomic” endograft deployment in ana-
tomically suitable conditions as a preferred approach.
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